Aardvark Therapeutics, Inc. Common Stock (AARD) vs MaxCyte, Inc. (MXCT)

A side-by-side comparison of Aardvark Therapeutics, Inc. Common Stock and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AARD

Aardvark Therapeutics, Inc. Common Stock

$109M

$5.00HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT

MXCT

MaxCyte, Inc.

$115M

$1.07HealthcareDelayed quote: Oct 6, 2026, 10:54 AM EDT

Total return — AARD vs MXCT

growth of $100 · dividends reinvested · last 2y

AARD -63.5% (-39.6%/yr)MXCT -74.3% (-49.3%/yr)AARD compounded faster over this window

AARD MXCT

AARD vs MXCT: by the numbers

•MXCT is the larger company ($115M vs $109M market cap).
•Both run net losses; AARD's is the smaller (0.00% vs -114.77% net margin).

Metrics side by side

Valuation

Metric	AARD	MXCT
P/S ratio	N/A	3.69
P/B ratio	1.46	0.72

Profitability

Metric	AARD	MXCT
Gross margin	0.00%	79.43%
Operating margin	0.00%	-137.12%
Net margin	0.00%	-114.77%
ROE	-93.44%	-22.45%
ROIC	-97.99%	-19.83%

Growth (annualized)

Metric	AARD	MXCT
Revenue CAGR (5Y)	N/A	1.46%
Total return CAGR (5Y)	N/A	-37.32%

Go deeper

Full AARD analysis Full MXCT analysis Interactive comparison tool

Dig into the metrics

Aardvark Therapeutics, Inc. Common Stock ROE MaxCyte ROE Aardvark Therapeutics, Inc. Common Stock operating margin MaxCyte operating margin Aardvark Therapeutics, Inc. Common Stock revenue growth MaxCyte revenue growth Aardvark Therapeutics, Inc. Common Stock free cash flow MaxCyte free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.